Cervix CancerNCT04258553
Thiol Disulfide Balance in Cervix Cancer
An observational study of Cervix Cancer and Oxidative Stress, run by Muğla Sıtkı Koçman University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this research is to evaluate thiol-disulfide balance in cervix cancer patients Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Cervix Cancer, Oxidative Stress
- What is being tested?
- Disulphide(μmol/L), Total Oxidant Capacity(μmolH2O2Equiv/L) and Ischemia Modified Albumin(IU/mL)
- How many people
- 123 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Sep 2018to 4 Feb 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: The preoperative diagnosis of cervix cancer was made histopathologically by cervical biopsy. An experienced pathologist performed pathological analysis according to the surgical staging scheme of the International Federation of Gynaecology and Obstetrics.
Who may be able to join
- Histopathologically confirmed diagnosis of cervix cancer
Who cannot join
- pulmonary disease
- pulmonary hypertension
- cardiac dysfunction
- renal dysfunction
- liver disease
- chronic ischemia
Show all 12Show fewer
- systemic inflammation
- concomitant malignancy
- patients who use vitamin A,C or E (antioxidant vitamins)
- patients who use smoke
- patients who use drink alcohol
- patients who use addictive for any drug
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Mugla Sıtkı Kocman University Faculty of Medicine
Muğla, 48000
About this study
Official title: Evaluation of Thiol Disulfide Balance in Cervix Cancer
The aim of this research is to evaluate thiol-disulfide balance in cervix cancer patients
Read the detailed description
To date various oxidative stress parameters were studied in patients with cervix cancer, however dynamic thiol disulfide hemostasis has not been previously investigated.
The thiol-disulfide balance in the circulation will be measured by the automated system created by Erel \& Neselioglu (1).
References
1- Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem 2014;47:326-32. doi:10.1016/j.clinbiochem.2014.09.026.
- Conditions
- Cervix Cancer, Oxidative Stress
- Being tested
- Disulphide(μmol/L), Total Oxidant Capacity(μmolH2O2Equiv/L), Ischemia Modified Albumin(IU/mL)
- Keywords
- thiol disulfide hemostasis, screening, early diagnosis
- Medical subject headings
- Uterine Cervical Neoplasms, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Disulphide(μmol/L)Diagnostic test
Also called Native thiol (μmol/L), Total thiol (μmol/L), Native thiol/totalthiol(%), Disulfide/native thiol(%)
Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
Total Oxidant Capacity(μmolH2O2Equiv/L)Diagnostic test
Also called Total Antioxidant Capacity(mmolTroloxEquiv/L), Oxidative stress Index (Arbitrary Unite)
Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
Ischemia Modified Albumin(IU/mL)Diagnostic test
The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).
| Study group | Role | What they receive |
|---|---|---|
| Cervix cancer | Cervix cancer n=62 Receives: Diagnostic Test: Disulphide(μmol/L); Diagnostic Test: Total Oxidant Capacity(μmolH2O2Equiv/L); Diagnostic Test: Ischemia Modified Albumin(IU/mL) | |
| Healthy controls | Healthy volunteers n=61 Receives: Diagnostic Test: Disulphide(μmol/L); Diagnostic Test: Total Oxidant Capacity(μmolH2O2Equiv/L); Diagnostic Test: Ischemia Modified Albumin(IU/mL) |
What is being measured
The primary outcome is the main question the study is designed to answer.
serum native thiol level
serum native thiol level in μmol/L
Measured: preoperative in the morning or preprandial for healthy volunteers
serum disulphide level
serum disulphide level in μmol/L
Measured: preoperative in the morning or preprandial for healthy volunteers
serum total thiol level
serum total thiol level in μmol/L
Measured: preoperative in the morning or preprandial for healthy volunteers
the disulphide/native thiol ratio
the disulphide/native thiol ratio X (100 )
Measured: preoperative in the morning or preprandial for healthy volunteers
disulphide/total thiol ratio
disulphide/total thiol ratio X (100 )
Measured: preoperative in the morning or preprandial for healthy volunteers
native thiol/total thiol ratio
native thiol/total thiol ratio X (100 )
Measured: preoperative in the morning or preprandial for healthy volunteers
Secondary outcomes (4)
total oxidant capacity (TOC)
TOC in mmol H2O2 equivalent/L
Measured: preoperative in the morning or preprandial for healthy volunteers
total antioxidant capacity (TAC)
TAC in mmol trolox equivalent/L
Measured: preoperative in the morning or preprandial for healthy volunteers
Oxidative stress index (OSI)
OSI in mmol trolox/L.
Measured: preoperative in the morning or preprandial for healthy volunteers
ischaemia-modified albumin
ischaemia-modified albumin in IU/mL
Measured: preoperative in the morning or preprandial for healthy volunteers
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Feb 2020
- Study start1 Sep 2018
- Primary completion20 Jan 2020
- Study completion4 Feb 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervix CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 123 participants (actual)
Sponsor and investigators
- Lead sponsor
- Muğla Sıtkı Koçman University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Burak Sezgin, Muğla Sıtkı Koçman University
- Investigators
- Burak Sezgin, MD, Principal investigator, Mugla Sıtkı Kocman University Faculty of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04258553
- Sponsor's protocol ID
- 19/09/2018-15-4
- Status last verified
- Apr 2020
- First submitted
- 4 Feb 2020
- Last updated
- 30 Apr 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Thiol Disulfide Balance in Cervix Cancer
- ClinicalTrials.gov ID
- NCT04258553
- Acronym / sponsor ID
- 19/09/2018-15-4
- Conditions
- Cervix Cancer, Oxidative Stress
- Keywords
- thiol disulfide hemostasis, screening, early diagnosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 123 participants (actual)
- Lead sponsor
- Muğla Sıtkı Koçman UniversityUniversity, hospital or other
- Study start
- 1 Sep 2018 (actual)
- Primary completion
- 20 Jan 2020 (actual)
- Study completion
- 4 Feb 2020 (actual)
- First posted
- 6 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this research is to evaluate thiol-disulfide balance in cervix cancer patients
Detailed description
To date various oxidative stress parameters were studied in patients with cervix cancer, however dynamic thiol disulfide hemostasis has not been previously investigated.
The thiol-disulfide balance in the circulation will be measured by the automated system created by Erel \& Neselioglu (1).
References
1- Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem 2014;47:326-32. doi:10.1016/j.clinbiochem.2014.09.026.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cervix cancer | – | Diagnostic Test: Disulphide(μmol/L), Diagnostic Test: Total Oxidant Capacity(μmolH2O2Equiv/L), Diagnostic Test: Ischemia Modified Albumin(IU/mL)Cervix cancer n=62 |
| Healthy controls | – | Diagnostic Test: Disulphide(μmol/L), Diagnostic Test: Total Oxidant Capacity(μmolH2O2Equiv/L), Diagnostic Test: Ischemia Modified Albumin(IU/mL)Healthy volunteers n=61 |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The preoperative diagnosis of cervix cancer was made histopathologically by cervical biopsy. An experienced pathologist performed pathological analysis according to the surgical staging scheme of the International Federation of Gynaecology and Obstetrics.
Key inclusion criteria (1 listed)
- Histopathologically confirmed diagnosis of cervix cancer
Key exclusion criteria (12 listed)
- pulmonary disease
- pulmonary hypertension
- cardiac dysfunction
- renal dysfunction
- liver disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Disulphide(μmol/L)Also: Native thiol (μmol/L), Total thiol (μmol/L), Native thiol/totalthiol(%), Disulfide/native thiol(%)Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry | Diagnostic test | Cervix cancer, Healthy controls |
| Total Oxidant Capacity(μmolH2O2Equiv/L)Also: Total Antioxidant Capacity(mmolTroloxEquiv/L), Oxidative stress Index (Arbitrary Unite)Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry | Diagnostic test | Cervix cancer, Healthy controls |
| Ischemia Modified Albumin(IU/mL)The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000). | Diagnostic test | Cervix cancer, Healthy controls |
Primary outcome
serum native thiol level
Time frame: preoperative in the morning or preprandial for healthy volunteers
serum native thiol level in μmol/L
serum disulphide level
Time frame: preoperative in the morning or preprandial for healthy volunteers
serum disulphide level in μmol/L
serum total thiol level
Time frame: preoperative in the morning or preprandial for healthy volunteers
serum total thiol level in μmol/L
the disulphide/native thiol ratio
Time frame: preoperative in the morning or preprandial for healthy volunteers
the disulphide/native thiol ratio X (100 )
disulphide/total thiol ratio
Time frame: preoperative in the morning or preprandial for healthy volunteers
disulphide/total thiol ratio X (100 )
native thiol/total thiol ratio
Time frame: preoperative in the morning or preprandial for healthy volunteers
native thiol/total thiol ratio X (100 )
4 secondary outcomes
total oxidant capacity (TOC)
Time frame: preoperative in the morning or preprandial for healthy volunteers
total antioxidant capacity (TAC)
Time frame: preoperative in the morning or preprandial for healthy volunteers
Oxidative stress index (OSI)
Time frame: preoperative in the morning or preprandial for healthy volunteers
ischaemia-modified albumin
Time frame: preoperative in the morning or preprandial for healthy volunteers
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2020.
- Individual participant dataSharing planned: Undecided
Related trials for Cervix Cancer
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
RecruitingPhase 3
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Enrolling by invitationObservational study
Use of cfDNA in Monitoring and Guiding Treatment for Cervical Cancer
Cervical Cancer Screening
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Burak Sezgin, MD principal investigator
Mugla Sıtkı Kocman University Faculty of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cervix Cancer and Oxidative Stress, run by Muğla Sıtkı Koçman University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
serum native thiol level (time frame: preoperative in the morning or preprandial for healthy volunteers). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2020.